JP7744240B2 - キレート化ａａｚｔａコンジュゲートおよびその錯体 - Google Patents

キレート化ａａｚｔａコンジュゲートおよびその錯体

Info

Publication number
JP7744240B2
JP7744240B2 JP2021525675A JP2021525675A JP7744240B2 JP 7744240 B2 JP7744240 B2 JP 7744240B2 JP 2021525675 A JP2021525675 A JP 2021525675A JP 2021525675 A JP2021525675 A JP 2021525675A JP 7744240 B2 JP7744240 B2 JP 7744240B2
Authority
JP
Japan
Prior art keywords
aazta
tate
metal
ion
nta
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021525675A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022507214A5 (https=
JP2022507214A (ja
Inventor
バラニャイ，ジョルト
ギアーニ，シモーナ
マイオッキ，アレッサンドロ
ハワラ，イヴァン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bracco Imaging SpA
Original Assignee
Bracco Imaging SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bracco Imaging SpA filed Critical Bracco Imaging SpA
Publication of JP2022507214A publication Critical patent/JP2022507214A/ja
Publication of JP2022507214A5 publication Critical patent/JP2022507214A5/ja
Priority to JP2023137271A priority Critical patent/JP2023179429A/ja
Application granted granted Critical
Publication of JP7744240B2 publication Critical patent/JP7744240B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/002—Heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0002—General or multifunctional contrast agents, e.g. chelated agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/14—Peptides, e.g. proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/083—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins the peptide being octreotide or a somatostatin-receptor-binding peptide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/64—Cyclic peptides containing only normal peptide links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Optics & Photonics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physics & Mathematics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
JP2021525675A 2018-11-12 2019-11-12 キレート化ａａｚｔａコンジュゲートおよびその錯体 Active JP7744240B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023137271A JP2023179429A (ja) 2018-11-12 2023-08-25 キレート化ａａｚｔａコンジュゲートおよびその錯体

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP18205796.8 2018-11-12
EP18205796 2018-11-12
PCT/EP2019/081014 WO2020099398A1 (en) 2018-11-12 2019-11-12 Chelating aazta conjugates and complexes thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023137271A Division JP2023179429A (ja) 2018-11-12 2023-08-25 キレート化ａａｚｔａコンジュゲートおよびその錯体

Publications (3)

Publication Number Publication Date
JP2022507214A JP2022507214A (ja) 2022-01-18
JP2022507214A5 JP2022507214A5 (https=) 2022-11-18
JP7744240B2 true JP7744240B2 (ja) 2025-09-25

Family

ID=64308553

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021525675A Active JP7744240B2 (ja) 2018-11-12 2019-11-12 キレート化ａａｚｔａコンジュゲートおよびその錯体
JP2023137271A Pending JP2023179429A (ja) 2018-11-12 2023-08-25 キレート化ａａｚｔａコンジュゲートおよびその錯体

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023137271A Pending JP2023179429A (ja) 2018-11-12 2023-08-25 キレート化ａａｚｔａコンジュゲートおよびその錯体

Country Status (5)

Country Link
US (1) US11684682B2 (https=)
EP (1) EP3880635B1 (https=)
JP (2) JP7744240B2 (https=)
CN (1) CN112996764B (https=)
WO (1) WO2020099398A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023179429A (ja) * 2018-11-12 2023-12-19 ブラッコ・イメージング・ソシエタ・ペル・アチオニ キレート化ａａｚｔａコンジュゲートおよびその錯体

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11541134B1 (en) 2021-08-02 2023-01-03 Rayzebio, Inc. Stabilized compositions of radionuclides and uses thereof
JP2025524769A (ja) 2022-07-28 2025-08-01 ブラッコ・イメージング・ソシエタ・ペル・アチオニ ２，４，６－トリヨードフェノール誘導体の製造方法
WO2025120059A1 (en) 2023-12-06 2025-06-12 Bracco Imaging Spa Compound for disorders associated with excess and/or accumulation of iron ions

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009505946A (ja) 2005-06-24 2009-02-12 ブラッコ・イメージング・ソシエタ・ペル・アチオニ 金属イオンと錯体を形成しうる多座アザ配位子ならびに診断および治療におけるその使用
JP2010512369A (ja) 2006-12-11 2010-04-22 ブラッコ・イメージング・ソシエタ・ペル・アチオニ 診断および治療適用用フィブリン結合ペプチドコンジュゲート
JP2010522727A (ja) 2007-03-28 2010-07-08 ゲルベ Ｖｃａｍ発現に関係する疾病の診断用化合物
US20180221499A1 (en) 2015-10-28 2018-08-09 Tarveda Therapeutics, Inc. Sstr-targeted conjugates and particles and formulations thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITMI20011518A1 (it) 2001-07-17 2003-01-17 Bracco Imaging Spa Leganti azotati multidentati capaci di complessare ioni metallici e loro uso in diagnostica e in terapia
WO2006002873A2 (en) 2004-07-02 2006-01-12 Bracco Imaging Spa 1 , 4 -bis (carboxymethyl) -6- ' bis ( carboxymethyl) amino ! -6 -methyl- perhydro-1 , 4 diazepine (aazta) derivatives as ligands in high relaxivity contrast agents for use in magnetic resonance imaging (mri )
EP1964846A1 (en) * 2007-02-27 2008-09-03 Bracco Imaging, S.P.A. Process for the preparation of contrast agents
EP2639227A1 (en) 2012-03-14 2013-09-18 Bracco Imaging S.p.A A new class of diazepine derivative chelating agents and complexes with paramagnetic metals as MRI contrast agents
WO2016016272A1 (en) * 2014-07-28 2016-02-04 Institut National De La Sante Et De La Recherche Medicale (Inserm) Macrocyclic complexes, their process of preparation and use as pet imaging agents
DE102014115154A1 (de) * 2014-10-17 2016-04-21 SCV-SpezialChemikalien-Vertrieb GmbH Konjugierte Bisphosphonate für die Diagnostik und Therapie von Knochenerkrankungen
CN112996764B (zh) * 2018-11-12 2023-11-21 伯拉考成像股份公司 螯合aazta缀合物及其配合物
CN213135750U (zh) * 2020-08-28 2021-05-07 苏州信毅捷自动化科技有限公司 一种便于拆卸的曲柄压装设备

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009505946A (ja) 2005-06-24 2009-02-12 ブラッコ・イメージング・ソシエタ・ペル・アチオニ 金属イオンと錯体を形成しうる多座アザ配位子ならびに診断および治療におけるその使用
JP2010512369A (ja) 2006-12-11 2010-04-22 ブラッコ・イメージング・ソシエタ・ペル・アチオニ 診断および治療適用用フィブリン結合ペプチドコンジュゲート
JP2010522727A (ja) 2007-03-28 2010-07-08 ゲルベ Ｖｃａｍ発現に関係する疾病の診断用化合物
US20180221499A1 (en) 2015-10-28 2018-08-09 Tarveda Therapeutics, Inc. Sstr-targeted conjugates and particles and formulations thereof

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023179429A (ja) * 2018-11-12 2023-12-19 ブラッコ・イメージング・ソシエタ・ペル・アチオニ キレート化ａａｚｔａコンジュゲートおよびその錯体

Also Published As

Publication number Publication date
US11684682B2 (en) 2023-06-27
WO2020099398A1 (en) 2020-05-22
JP2023179429A (ja) 2023-12-19
EP3880635B1 (en) 2023-01-04
CN112996764A (zh) 2021-06-18
EP3880635A1 (en) 2021-09-22
CN112996764B (zh) 2023-11-21
US20220016275A1 (en) 2022-01-20
JP2022507214A (ja) 2022-01-18

Similar Documents

Publication Publication Date Title
Maecke et al. 68Ga-PET radiopharmacy: a generator-based alternative to 18F-radiopharmacy
JP7744240B2 (ja) キレート化ａａｚｔａコンジュゲートおよびその錯体
Failla et al. Peptide-based positron emission tomography probes: current strategies for synthesis and radiolabelling
BR112020001785A2 (pt) radiotraçador e compostos radioterapêuticos bimodais
AU2019469641B2 (en) Radiolabeled bombesin-derived compounds for in vivo imaging of gastrin-releasing peptide receptor (GRPR) and treatment of GRPR-related disorders
Honarvar et al. Evaluation of the first 44Sc-labeled Affibody molecule for imaging of HER2-expressing tumors
KR20220063214A (ko) Grpr 길항제의 방사성표지 방법 및 이의 키트
AU2023347470A1 (en) High-purity copper radiopharmaceutical compositions and diagnostic and therapeutic uses thereof
WO2014117001A1 (en) Tetrazines/trans-cyclooctenes in solid phase synthesis of labeled peptides
US20110117012A1 (en) Radiolabeled gallium complexes, methods for synthesis and use for pet imaging of egfr expression in malignant tumors
CA3136979A1 (en) Radiolabelled compounds for diagnosis or treatment of prostate-spe cific membrane antigen-expressing cancer
Wharton et al. Rearmed bifunctional chelating ligand for 225Ac/155Tb Precision-guided theranostic radiopharmaceuticals─ H4noneunpaX
JP2003517037A (ja) 新規ソマトスタチン類似体
EP2056886A2 (en) 68ga-labeled peptide-based radiopharmaceuticals
Giblin et al. Radiometallation of receptor-specific peptides for diagnosis and treatment of human cancer
Ishizaki et al. Fundamental study of radiogallium-labeled aspartic acid peptides introducing octreotate derivatives
Boros et al. Coordination chemistry and ligand design in the development of metal based radiopharmaceuticals
JP2008538204A (ja) 安定化側鎖を含む放射性標識複合体キレート剤
KR101551232B1 (ko) Ｎ3ｓ1형의 새로운 킬레이터가 접합된 폴레이트 유도체, 이의 제조방법 및 이를 유효성분으로 함유하는 암 진단 또는 치료용 조성물
Ferro-Flores et al. Peptide labeling using 188Re, 188Re-MAG3 and 153Sm-H1ETA: A comparison on their in vitro lipophilicity
WO2025171887A1 (en) Radiolabeled complexes and pharmaceutical compositions including the same
Merdžo Sviluppo di nuovi modelli di radiofarmaci a base di metalli per imaging e terapia
Floresta et al. RSC Medicinal Chemistry
Dos Santos Development of inhibitors of the prostate specific membrane antigen (PSMA) for imaging and endoradiotherapy
Thapa Fluorine-18 labeling and simultaneous glycosylation of the model peptide demobesin 1 by the novel prosthetic group, keto-[18 F] FDG

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221109

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20221109

A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20221109

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20221213

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230313

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20230425

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250612

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20250911

R150 Certificate of patent or registration of utility model

Ref document number: 7744240

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150